Literature DB >> 31108561

SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma.

Astrid K Gnekow1, Daniela Kandels1, Cornelis van Tilburg2,3, Amedeo A Azizi4, Enrico Opocher5, Tore Stokland6, Pablo Hernaiz Driever7, A Y N Schouten-van Meeteren8, Ulrich W Thomale9, Martin U Schuhmann10, Thomas Czech11, John Robert Goodden12, Monika Warmuth-Metz13, Brigitte Bison13, Shivaram Avula14, Rolf-D Kortmann15, Beate Timmermann16, Torsten Pietsch17, Olaf Witt2,3.   

Abstract

Low grade gliomas (LGGs) constitute the largest, yet clinically and (molecular-) histologically heterogeneous group of pediatric brain tumors of WHO grades I and II occurring throughout all pediatric age groups and at all central nervous system (CNS) sites. The tumors are characterized by a slow growth rate and may show periods of growth arrest. Around 40% of all LGG patients can be cured by complete neurosurgical resection and are followed by close observation. In case of relapse, second resection often is possible. Following incomplete resection observation is recommended, as long as there is no radiologic tumor growth and the patient does not suffer from significant, tumor-related symptoms. This also applies to patients with a diagnosis of LGG on the basis of radiological criteria. By contrast, clinical worsening and / or radiologic progression are an indication to treatment with either chemo- or radiotherapy. Overall survival is around 90%, and many patients survive with residual tumor, i. e. they suffer from chronic disease. All patients need comprehensive neuro-oncological care, the principles and details of which are summarized in the current guidelines. These represent standard of care for diagnostic work-up (including neuroimaging and neuropathology), and for therapeutic decisions (including the indications to non-surgical treatment) as well as concepts for neurosurgical intervention, chemotherapy and radiotherapy as well as surveillance and rehabilitation. The current treatment algorithm was compiled by members of the LGG working group of the SIOP-E brain tumor group (SIOP-E-BTG) and is based upon the results of previous European LGG studies and international reports. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2019        PMID: 31108561     DOI: 10.1055/a-0889-8256

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  18 in total

1.  Neurofibromatosis 1-associated optic pathway gliomas.

Authors:  Ben Shofty; Liat Ben Sira; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-11       Impact factor: 1.475

Review 2.  Thalamic tumors in children: case series from our institution and literature review.

Authors:  Daniela Renedo; Florencia Ferraro; Agustín Ruiz Johnson; Romina Argañaraz; Sebastian Giovannini; Joaquín Pérez Zabala; Elena Zemma; Beatriz Mantese
Journal:  Childs Nerv Syst       Date:  2020-07-25       Impact factor: 1.475

Review 3.  European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours.

Authors:  Shivaram Avula; Andrew Peet; Giovanni Morana; Paul Morgan; Monika Warmuth-Metz; Tim Jaspan
Journal:  Childs Nerv Syst       Date:  2021-05-10       Impact factor: 1.475

4.  Trigeminal nerve chronic motor denervation caused by cerebellar peduncle pilocytic astrocytoma.

Authors:  Danai Papangelopoulou; Marc Ansari; Andrea Bartoli; Joel Fluss; Andre O von Bueren
Journal:  Childs Nerv Syst       Date:  2021-01-22       Impact factor: 1.475

5.  Retrospective analysis of combination carboplatin and vinblastine for pediatric low-grade glioma.

Authors:  Anandani Nellan; Erin Wright; Kristen Campbell; Kurtis D Davies; Andrew M Donson; Vladimir Amani; Alexis Judd; Molly S Hemenway; Jennifer Raybin; Nicholas K Foreman; Sarah Rush; Kathleen Dorris
Journal:  J Neurooncol       Date:  2020-06-06       Impact factor: 4.130

6.  MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression.

Authors:  Giuseppina Catanzaro; Zein Mersini Besharat; Andrea Carai; Natalie Jäger; Elena Splendiani; Carole Colin; Agnese Po; Martina Chiacchiarini; Anna Citarella; Francesca Gianno; Antonella Cacchione; Evelina Miele; Francesca Diomedi Camassei; Marco Gessi; Luca Massimi; Franco Locatelli; David T W Jones; Dominique Figarella-Branger; Stefan M Pfister; Angela Mastronuzzi; Felice Giangaspero; Elisabetta Ferretti
Journal:  Biomark Res       Date:  2022-06-17

7.  What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry.

Authors:  Misa Matsuyama; Mythily Sachchithananthan; Robyn Leonard; Michael Besser; Anna K Nowak; Donna Truran; Claire M Vajdic; John R Zalcberg; Hui K Gan; Craig Gedye; Winny Varikatt; Eng-Siew Koh; Ganessan Kichenadasse; Hao-Wen Sim; Nicholas G Gottardo; Desma Spyridopoulos; Rosalind L Jeffree
Journal:  Neurooncol Pract       Date:  2021-08-31

8.  High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group.

Authors:  Thomas Perwein; Martin Benesch; Daniela Kandels; Torsten Pietsch; René Schmidt; Franz Quehenberger; Brigitte Bison; Monika Warmuth-Metz; Beate Timmermann; Jürgen Krauss; Ulrich-Wilhelm Thomale; Rolf-Dieter Kortmann; Pablo Hernáiz Driever; Astrid Katharina Gnekow
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

9.  Evaluation of the reporting quality of clinical practice guidelines on gliomas using the RIGHT checklist.

Authors:  Yongjie Yang; Yanfang Ma; Jingli Lu; Shuzhang Du; Jingmin Zhang; Haiyang Meng; Zhe Chen; Qiwen Zhang; Xiaojian Zhang; Wenyin Shi; Francesco Girolamo; Santiago Cepeda; Jian Kang
Journal:  Ann Transl Med       Date:  2021-06

Review 10.  Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.

Authors:  Till Milde; Fausto J Rodriguez; Jill S Barnholtz-Sloan; Nirav Patil; Charles G Eberhart; David H Gutmann
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.